Meeting the Challenge of Eliminating Chronic Hepatitis B Infection

doi:10.3390/genes10040260

Review

. 2019 Apr 1;10(4):260.

doi: 10.3390/genes10040260.

Meeting the Challenge of Eliminating Chronic Hepatitis B Infection

Peter A Revill^{1

2}, Capucine Penicaud³, Christian Brechot^{4

5

6}, Fabien Zoulim⁷

Affiliations

¹ Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Australia. peter.revill@mh.org.au.
² Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Australia. peter.revill@mh.org.au.
³ Directorate, Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Australia. Capucine.Penicaud@unimelb.edu.au.
⁴ University of South Florida, Tampa, 33612, USA. christian.brechot@pasteur.fr.
⁵ Romark Laboratory, Tampa, 33607, USA. christian.brechot@pasteur.fr.
⁶ Global Virus Network, Baltimore; MD 21201-1009, USA. christian.brechot@pasteur.fr.
⁷ INSERM Unit 1052-Cancer Research Center of Lyon, 69000 Lyon, France. fabien.zoulim@inserm.fr.

PMID: 30939846
PMCID: PMC6523454
DOI: 10.3390/genes10040260

Review

Meeting the Challenge of Eliminating Chronic Hepatitis B Infection

Peter A Revill et al. Genes (Basel). 2019.

. 2019 Apr 1;10(4):260.

doi: 10.3390/genes10040260.

Authors

Peter A Revill^{1

2}, Capucine Penicaud³, Christian Brechot^{4

5

6}, Fabien Zoulim⁷

Affiliations

¹ Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Australia. peter.revill@mh.org.au.
² Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Australia. peter.revill@mh.org.au.
³ Directorate, Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Australia. Capucine.Penicaud@unimelb.edu.au.
⁴ University of South Florida, Tampa, 33612, USA. christian.brechot@pasteur.fr.
⁵ Romark Laboratory, Tampa, 33607, USA. christian.brechot@pasteur.fr.
⁶ Global Virus Network, Baltimore; MD 21201-1009, USA. christian.brechot@pasteur.fr.
⁷ INSERM Unit 1052-Cancer Research Center of Lyon, 69000 Lyon, France. fabien.zoulim@inserm.fr.

PMID: 30939846
PMCID: PMC6523454
DOI: 10.3390/genes10040260

Abstract

Over 257 million people live with chronic hepatitis B virus (HBV) infection and there is no known cure. The effective preventative vaccine has no impact on existing infection. Despite the existence of drugs which efficiently suppress viral replication, treatment is usually life-long and finite therapies that cure HBV infection are urgently required. However, even if such therapies were available today, it is unlikely they would reach all of those who need it most, due to chronic hepatitis B (CHB) being largely undiagnosed across the globe and to the dire need for health systems promoting access to therapy. Considerable challenges to developing and implementing an effective HBV cure remain. Nonetheless, important advances towards a cure are being made, both in the development of a multitude of new therapeutic agents currently undergoing clinical trials, and through the establishment of a new global initiative dedicated to an HBV cure, ICE-HBV, that is working together with existing organisations to fast-track an HBV cure available to all.

Keywords: HBV cure; ICE-HBV; chronic HBV disease; current clinical trials; persistence; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

**Figure 1**
Current and future International Coalition to Eliminate Hepatitis B (ICE-HBV) projects to fast-track a hepatitis B virus (HBV) cure.

See this image and copyright information in PMC

Cited by

Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
GBD 2019 Hepatitis B Collaborators. GBD 2019 Hepatitis B Collaborators. Lancet Gastroenterol Hepatol. 2022 Sep;7(9):796-829. doi: 10.1016/S2468-1253(22)00124-8. Epub 2022 Jun 21. Lancet Gastroenterol Hepatol. 2022. PMID: 35738290 Free PMC article.
Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial.
Wu QJ, Lv WL, Li JM, Zhang TT, Zhou WH, Zhang Q, Wang JC, Wang QN, Zhang RX, Zhao X, Chen ST, Liu S, Li GH, Cao ZM, Xu L, Chen J. Wu QJ, et al. Trials. 2020 Jun 5;21(1):482. doi: 10.1186/s13063-020-04395-y. Trials. 2020. PMID: 32503608 Free PMC article.
Impact of RNA Virus Evolution on Quasispecies Formation and Virulence.
Mandary MB, Masomian M, Poh CL. Mandary MB, et al. Int J Mol Sci. 2019 Sep 19;20(18):4657. doi: 10.3390/ijms20184657. Int J Mol Sci. 2019. PMID: 31546962 Free PMC article. Review.
A Current Management Strategy for Children with Chronic Viral Hepatitis B, Based on International and National Guidelines.
Nesina IM, Kryuchko TO, Poda OA, Tkachenko OY, Kuzmenko NV, Bubyr LM. Nesina IM, et al. J Mother Child. 2023 Aug 31;27(1):134-141. doi: 10.34763/jmotherandchild.20232701.d-23-00006. eCollection 2023 Jun 1. J Mother Child. 2023. PMID: 37668440 Free PMC article. Review.
Current Challenges and Future Perspectives of Diagnosis of Hepatitis B Virus.
Kumar M, Pahuja S, Khare P, Kumar A. Kumar M, et al. Diagnostics (Basel). 2023 Jan 19;13(3):368. doi: 10.3390/diagnostics13030368. Diagnostics (Basel). 2023. PMID: 36766473 Free PMC article. Review.

See all "Cited by" articles

References

1. World Health Organization Hepatitis B Fact Sheet. [(accessed on 10 December 2018)]; Available online: http://www.who.int/mediacentre/factsheets/fs204/en/
1. Revill P., Testoni B., Locarnini S., Zoulim F. Global strategies are required to cure and eliminate HBV infection. Nat. Rev. Gastroenterol. Hepatol. 2016;13:239–248. doi: 10.1038/nrgastro.2016.7. - DOI - PubMed
1. Zeisel M.B., Lucifora J., Mason W.S., Sureau C., Beck J., Levrero M., Kann M., Knolle P.A., Benkirane M., Durantel D., et al. Towards an HBV cure: State-of-the-art and unresolved questions—Report of the ANRS workshop on HBV cure. Gut. 2015;64:1314–1326. doi: 10.1136/gutjnl-2014-308943. - DOI - PubMed
1. Zoulim F., Testoni B., Lebosse F. Kinetics of intrahepatic covalently closed circular DNA and serum hepatitis B surface antigen during antiviral therapy for chronic hepatitis B: Lessons from experimental and clinical studies. Clin. Gastroenterol. Hepatol. 2013;11:1011–1013. doi: 10.1016/j.cgh.2013.04.010. - DOI - PubMed
1. Lok A.S., Zoulim F., Dusheiko G., Ghany M.G. Hepatitis B cure: From discovery to regulatory approval. Hepatology. 2017;66:1296–1313. doi: 10.1002/hep.29323. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources

[1] World Health Organization Hepatitis B Fact Sheet. [(accessed on 10 December 2018)]; Available online: http://www.who.int/mediacentre/factsheets/fs204/en/

[2] World Health Organization Hepatitis B Fact Sheet. [(accessed on 10 December 2018)]; Available online: http://www.who.int/mediacentre/factsheets/fs204/en/

[3] Revill P., Testoni B., Locarnini S., Zoulim F. Global strategies are required to cure and eliminate HBV infection. Nat. Rev. Gastroenterol. Hepatol. 2016;13:239–248. doi: 10.1038/nrgastro.2016.7. - DOI - PubMed

[4] Revill P., Testoni B., Locarnini S., Zoulim F. Global strategies are required to cure and eliminate HBV infection. Nat. Rev. Gastroenterol. Hepatol. 2016;13:239–248. doi: 10.1038/nrgastro.2016.7. - DOI - PubMed

[5] Zeisel M.B., Lucifora J., Mason W.S., Sureau C., Beck J., Levrero M., Kann M., Knolle P.A., Benkirane M., Durantel D., et al. Towards an HBV cure: State-of-the-art and unresolved questions—Report of the ANRS workshop on HBV cure. Gut. 2015;64:1314–1326. doi: 10.1136/gutjnl-2014-308943. - DOI - PubMed

[6] Zeisel M.B., Lucifora J., Mason W.S., Sureau C., Beck J., Levrero M., Kann M., Knolle P.A., Benkirane M., Durantel D., et al. Towards an HBV cure: State-of-the-art and unresolved questions—Report of the ANRS workshop on HBV cure. Gut. 2015;64:1314–1326. doi: 10.1136/gutjnl-2014-308943. - DOI - PubMed

[7] Zoulim F., Testoni B., Lebosse F. Kinetics of intrahepatic covalently closed circular DNA and serum hepatitis B surface antigen during antiviral therapy for chronic hepatitis B: Lessons from experimental and clinical studies. Clin. Gastroenterol. Hepatol. 2013;11:1011–1013. doi: 10.1016/j.cgh.2013.04.010. - DOI - PubMed

[8] Zoulim F., Testoni B., Lebosse F. Kinetics of intrahepatic covalently closed circular DNA and serum hepatitis B surface antigen during antiviral therapy for chronic hepatitis B: Lessons from experimental and clinical studies. Clin. Gastroenterol. Hepatol. 2013;11:1011–1013. doi: 10.1016/j.cgh.2013.04.010. - DOI - PubMed

[9] Lok A.S., Zoulim F., Dusheiko G., Ghany M.G. Hepatitis B cure: From discovery to regulatory approval. Hepatology. 2017;66:1296–1313. doi: 10.1002/hep.29323. - DOI - PMC - PubMed

[10] Lok A.S., Zoulim F., Dusheiko G., Ghany M.G. Hepatitis B cure: From discovery to regulatory approval. Hepatology. 2017;66:1296–1313. doi: 10.1002/hep.29323. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Meeting the Challenge of Eliminating Chronic Hepatitis B Infection

Affiliations

Meeting the Challenge of Eliminating Chronic Hepatitis B Infection

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources